Zilebesiran - A New Hypertension Treatment

Injectable, long-acting therapy is a new frontier for hypertension management. Join host, Geoff Wall, as he evaluates zilebesiran, a hepatic angiotensinogen blocker for blood pressure control for up to six months. The GameChanger Zilebesiran blocks the final production of angiotensinogen at the hepatic level making it safer from a renal perspective than the ACEis or ARBs. A single subcutaneous injection provides therapy for up to six months. Host Geoff Wall, PharmD, BCPS, FCCP, BCGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health Reference Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20;389(3):228-238. doi: 10.1056/NEJMoa2208391. PMID: 37467498. https://www.nejm.org/doi/full/10.1056/NEJMoa2208391 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE Information Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe the mechanism of action of Zilebesiran 2. Discuss possible advantages and disadvantages of this drug in the treatment of hypertension 0.05 CEU/0.5 Hr UAN: 0107-0000-23-323-H01-P Initial release date: 10/16 /2023 Expiration date: 10/16/2024 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram